Biomarin Price To Sales Ratio from 2010 to 2025

BMRN Stock  USD 68.25  0.48  0.70%   
Biomarin Pharmaceutical Price To Sales Ratio yearly trend continues to be very stable with very little volatility. Price To Sales Ratio is likely to drop to 4.16. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Biomarin Pharmaceutical's market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
4.37661062
Current Value
4.16
Quarterly Volatility
59.00181434
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 126 M, Interest Expense of 17.9 M or Selling General Administrative of 542 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.99. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Biomarin Pharmaceutical over the last few years. Price to Sales Ratio is figured by comparing Biomarin Pharmaceutical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Biomarin Pharmaceutical sales, a figure that is much harder to manipulate than other Biomarin Pharmaceutical multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Biomarin Pharmaceutical's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 4.56 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
8.888.528.759.157.494.384.16-4%3%5%-18%-42%-5%100%
       Timeline  

Biomarin Price To Sales Ratio Regression Statistics

Arithmetic Mean25.39
Geometric Mean11.98
Coefficient Of Variation232.39
Mean Deviation27.58
Median10.11
Standard Deviation59.00
Sample Variance3,481
Range242
R-Value(0.47)
Mean Square Error2,917
R-Squared0.22
Significance0.07
Slope(5.79)
Total Sum of Squares52,218

Biomarin Price To Sales Ratio History

2025 4.16
2024 4.38
2023 7.49
2022 9.15
2021 8.75
2020 8.52
2019 8.88

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price To Sales Ratio 4.38  4.16 
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.393
Earnings Share
2.21
Revenue Per Share
15.018
Quarterly Revenue Growth
0.156
Return On Assets
0.0515
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Discover investing ideas

Utilize additional investing modules

N…I…100%